Hansa Biopharma OM:HNSA Stock Report

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 results: kr3.82 loss per share (down from kr2.98 loss in 2Q 2021). Revenue: kr26.4m (up 482% from 2Q 2021). Net loss: kr170.1m (loss widened 28% from 2Q 2021). Revenue exceeded analyst estimates by 76%. Earnings per share (EPS) missed analyst estimates by 104%. Over the next year, revenue is forecast to grow 76%, compared to a 167% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB announced that the first patient has been treated in the PAES for Idefirix® as a desensitization treatment for highly sensitized people undergoing a kidney transplant.This open-label Phase 3 study will enroll 50 highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor to confirm the long-term efficacy and safety of Idefirix®. The PAES is an obligation under the conditional marketing authorization for Idefirix® granted by EMA in August 2020, in order to complete a full marketing authorization for the European Union. The PAES will enrol patients across multiple countries and centers in Europe and the study will include 50 highly sensitized and crossmatch positive patients to be treated with Idefirix®. The aim of the study is to confirm the long-term efficacy and safety of Idefirix® and the primary objective of the study is to determine the 1-year graft failure-free survival of the Idefirix® treated and transplanted patients. In addition, a total of 50-100 patients undergoing compatible kidney transplantation at the participating centers will be included and serve as a non-comparative concurrent reference cohort, with no formal comparison, to contextualize the 1-year graft failure-free survival of the Idefirix® treated patients.